Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term endothelin A receptor blockade in patients undergoing on-pump CABG
2010-023552-90Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Dec 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of BQ-123 in coronary arteriosclerosis and Coronary artery bypass graft (CABG), sponsored by Medical University of Vienna. Primary endpoint: Coronary artery bypass graft blood flow. Started Dec 2010; status: terminated.
02
Drugs
BQ-123
03
Conditions
coronary arteriosclerosisCoronary artery bypass graft (CABG)
Beyond the preview
Go deeper on 2010-023552-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023552-90.